N3-Arylmalonamides: A new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases
摘要:
A family of thieno[3,2-b]pyridine based small molecule inhibitors of c-Met and VEGFR2 were designed based on lead structure 2. These compounds were shown to have IC50 values in the low nanomolar range in vitro and were efficacious in human tumor xenograft models in mice in vivo. (C) 2009 Elsevier Ltd. All rights reserved.
Inhibitors of VEGF receptor and HGF receptor signaling
申请人:Saavedra Mario Oscar
公开号:US20070004675A1
公开(公告)日:2007-01-04
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
申请人:Carter H. Percy
公开号:US20050054626A1
公开(公告)日:2005-03-10
The present application describes modulators of MCP-1 of formula (I):
or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
Malonamides and malonamide derivatives as modulators of chemokine receptor activity
申请人:——
公开号:US20040235835A1
公开(公告)日:2004-11-25
The present application describes modulators of MCP-1 of formula (I):
1
or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
Cyclic derivatives as modulators of chemokine receptor activity
申请人:——
公开号:US20040235836A1
公开(公告)日:2004-11-25
The present application describes modulators of MCP-1 of formula (I):
1
or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
申请人:Carter Percy
公开号:US20070213379A1
公开(公告)日:2007-09-13
The present application describes modulators of MCP-1 of formula (I):
or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.